300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Social Impact
Oil and Gas
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Music
Wine and Spirits
Food and Beverage
Publishing
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Art
Franchise
Mobile Advertising
Non Profit
Internet
Android
Real Estate
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Sporting Goods
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Taiwan
Liberia
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Tunisia
Isle of Man
Madagascar
Pakistan
Sweden
Romania
Zimbabwe
Zambia
Norway
Tajikistan
Puerto Rico
Oman
Poland
Sudan
Cameroon
Guernsey
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Morocco
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Paraguay
Seychelles
Botswana
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
United States
Germany
India
Indonesia
Middle East
Asia
Dominican Republic
Bermuda
Albania
Argentina
Spain
Angola
Europe
Cyprus
Bangladesh
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Bahamas
Ecuador
Bolivia
Algeria
Belize
Finland
Faroe Islands
Italy
Estonia
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Jersey
Bahrain
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotech VC Funds & Investors in Denmark (August 2026)

The most active venture capital funds investing in Denmark Biotech startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Denmark Biotech startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Novo Holdings
VC Fund
33 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $9.9M–$135M
BioInnovation Institute
VC Fund
28 Denmark, Germany, Switzerland Convertible Note, Pre-Seed, Seed Biotechnology, Medical, Health Care $495k–$5.2M
Export and Investment Fund
VC Fund
20 Denmark, United States, United Kingdom Seed, Series A Software, Biotechnology, Health Care $457k–$43M
Vaekstfonden
VC Fund
18 Denmark, United States, United Kingdom Seed, Pre-Seed Software, Information Technology, SaaS $384k–$5.3M
Seed Capital
VC Fund
9 Denmark, United States, United Kingdom Seed, Series A Software, Health Care, SaaS $549k–$17M
PSV
VC Fund
7 Denmark, United States, United Kingdom Seed, Pre-Seed Software, Information Technology, SaaS $353k–$4.6M
Sunstone Life Science Ventures
VC Fund
6 Denmark, Sweden, Switzerland Series A, Series B Biotechnology, Health Care, Medical $5.5M–$52M
Gilde Healthcare
VC Fund
6 United States, The Netherlands, Germany Series B, Series C, Series A Health Care, Biotechnology, Medical $9.5M–$135M
Oskare Capital
VC Fund
6 Italy, Denmark, United Kingdom Seed, Series A, Pre-Seed Health Care, Biotechnology, Medical $1.2M–$5.9M
Nordic Foodtech VC
VC Fund
6 Finland, Denmark, Sweden Seed, Pre-Seed, Series A Biotechnology, Food and Beverage, Life Science $610k–$18M
The Footprint Firm
VC Fund
5 Denmark, Spain, Norway Seed, Pre-Seed, Series A Software, Renewable Energy, Energy Management $863k–$18M
RA Capital Management
VC Fund
5 United States, United Kingdom, Canada Series B, Series C, Post-IPO Equity Biotechnology, Health Care, Therapeutics $27M–$240M
2xN
VC Fund
5 Denmark, United States, Finland Seed, Series A, Series B Software, Information Technology, Quantum Computing $1.9M–$63M
West Hill Capital
VC Fund
5 United Kingdom, Denmark, Germany Series A, Seed Software, Health Care, Financial Services $2M–$15M
HealthCap
VC Fund
4 United States, Sweden, France Series B, Series A Biotechnology, Health Care, Medical $5.7M–$92M
ACME Capital
VC Fund
4 United States, Denmark, Canada Seed, Series A, Series B Software, Health Care, Mobile $1.6M–$70M
VF Venture
VC Fund
4 Denmark, United Kingdom, Iceland Seed, Series A Software, SaaS, Biotechnology $1.2M–$22M
PINC
VC Fund
4 Sweden, Denmark, United Kingdom Seed, Pre-Seed, Series A Biotechnology, Food and Beverage, Agriculture $89k–$7.2M
DSM Venturing
VC Fund
4 United States, Canada, Israel Series A, Series B Health Care, Biotechnology, Manufacturing $3.5M–$32M
Ysios Capital
VC Fund
4 Spain, United States, Switzerland Series A, Series B, Series C Biotechnology, Health Care, Medical $3.8M–$135M
EIR Ventures
VC Fund
4 Denmark, Sweden, United States Series A, Seed Biotechnology, Health Care, Therapeutics $20M–$73M
Atlantic
VC Fund
4 Germany, Switzerland, United States Seed, Pre-Seed, Series A Software, Health Care, Artificial Intelligence $850k–$30M
Sofinnova Partners
VC Fund
3 France, United States, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $6.6M–$109M
Unconventional Ventures
VC Fund
3 Sweden, Denmark, United Kingdom Seed, Pre-Seed, Series A Health Care, Software, Wellness $1M–$18M
HTGF (High-Tech Gruenderfonds)
VC Fund
3 Germany, Switzerland, United States Seed, Series A Software, Biotechnology, Information Technology $909k–$39M
Karolinska
VC Fund
3 Sweden, Denmark, United States Seed, Series A Biotechnology, Health Care, Pharmaceutical $1.3M–$73M
Innovation Fund Denmark
VC Fund
3 Denmark, United States Grant, Pre-Seed, Seed Software, Biotechnology, SaaS $35k–$1.6M
Bioqube Ventures
VC Fund
3 United States, France, Norway Seed, Series A, Series B Biotechnology, Therapeutics, Life Science $4M–$108M
Lundbeckfonden Ventures
VC Fund
3 United States, Denmark, United Kingdom Series B, Series A, Series C Biotechnology, Health Care, Therapeutics $10M–$95M
Blue Horizon Corporation
VC Fund
3 United States, United Kingdom, Germany Seed, Series A, Pre-Seed Food and Beverage, Food Processing, Biotechnology $450k–$40M
NOON Ventures
VC Fund
3 Denmark Seed, Series A Biotechnology, AgTech, Farming $4.3M–$8.8M
Dawn Biopharma
VC Fund
3 United States, Denmark, France Series A, Seed, Series B Biotechnology, Health Care, Therapeutics $15M–$165M
Thia Ventures
VC Fund
3 United States, France, Denmark Series A, Seed, Pre-Seed Biotechnology, Health Care, Manufacturing $3.4M–$48M
Omega Funds
VC Fund
3 United States, Switzerland, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $14M–$208M
Ugly Duckling Ventures
VC Fund
3 Denmark, Sweden, Finland Seed, Pre-Seed, Venture - Series Unknown Software, Information Technology, Artificial Intelligence $876k–$7.5M
Novo Ventures
VC Fund
2 United States, United Kingdom, Switzerland Series B, Series A, Series C Biotechnology, Health Care, Medical $8.5M–$139M
+ND Capital
VC Fund
2 United States, Switzerland, Denmark Series B, Series C, Series A Biotechnology, Health Care, Medical
SR One
VC Fund
2 United States, United Kingdom, Canada Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $3.7M–$175M
M Ventures
VC Fund
2 United States, United Kingdom, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2.4M–$100M
FundersClub
VC Fund
2 United States, Canada, India Seed, Series A, Pre-Seed Software, Artificial Intelligence, SaaS $450k–$23M
Megatrend Invest
VC Fund
2 Denmark Seed Biotechnology, Manufacturing $3.3M–$10M
Seventure Partners
VC Fund
2 France, United States, Germany Series A, Series B Biotechnology, Health Care, Software $3.3M–$63M
Balderton Capital
VC Fund
2 United Kingdom, United States, Germany Series A, Series B, Series C Software, FinTech, Financial Services
Industrifonden
VC Fund
2 Sweden, United States, Denmark Series A, Seed Software, Biotechnology, Information Technology
SOSV
VC Fund
2 United States, India, United Kingdom Seed, Convertible Note, Pre-Seed Biotechnology, Health Care, Software
Aescap Venture
VC Fund
2 United Kingdom, Austria, Belgium Series A, Series B Biotechnology, Pharmaceutical, Chemical
Novo Nordisk
VC Fund
2 United States, Denmark, Canada Series A, Seed, Series B Biotechnology, Health Care, Therapeutics $1.6M–$115M
Innovations Kapital
VC Fund
2 Sweden, Denmark, United States Series B, Series C Biotechnology, Health Care, Software $5.5M–$30M
Symrise
VC Fund
2 United States, Sweden, Denmark Series A, Corporate Round, Seed Biotechnology, Health Care, Pet $4.2M–$7.2M
byFounders
VC Fund
2 Denmark, United States, Sweden Seed, Pre-Seed, Series A Software, Artificial Intelligence, Health Care $800k–$65M
Access all 351 VC funds in Denmark Biotech startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 33 investments in Denmark Biotech startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 370
  • Round size: Series A $9.9M–$133M; Series B $12M–$135M; Series C $30M–$118M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: May invest from a new fund soon — raised $165M in 2018

Portfolio highlights

  • Tarveda Therapeutics — Developing Pentarins to make a difference in the treatment of patients with solid tumor malignancies
  • Tarsa Therapeutics — Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Show all investments...

BioInnovation Institute
VC Fund · Copenhagen, Hovedstaden, Denmark · 28 investments in Denmark Biotech startups

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Convertible Note, Pre-Seed, Seed
  • Geography: Denmark, Germany, Switzerland

Investor stats

  • Total investments: 92
  • Round size: Seed $532k–$1.6M; Pre-Seed $516k–$5.2M; Convertible Note $495k–$1.6M
  • Lead/follow: 92% lead, 8% follow

Portfolio highlights

  • Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
  • Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
  • metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Show all investments...

Export and Investment Fund
VC Fund · Hellerup, Hovedstaden, Denmark · 20 investments in Denmark Biotech startups

Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: Denmark, United States, United Kingdom

Investor stats

  • Total investments: 136
  • Round size: Seed $457k–$11M; Series A $5.9M–$43M
  • Lead/follow: 36% lead, 64% follow

Portfolio highlights

  • EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
  • MATR Foods — MATR Foods is a food-tech startup that provides fungi-based food ingredients offering dishes produced from fungi like mushrooms, vegetables, and fruits.
  • VentriJect — VentriJect is a is a research facility that incorporates measuring cardiorespiratory fitness into everyone's checkup. They estimate respiratory fitness, which is a simple process. As a health indicator, people can increase their cardiorespiratory fitness. They have compiled a list of some of the other pertinent articles that relate to thesignificance of VO2-max measurement.
Show all investments...

Vaekstfonden
VC Fund · Hellerup, Hovedstaden, Denmark · 18 investments in Denmark Biotech startups

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Show more...

Investment focus

  • Industry: Software, Information Technology, SaaS
  • Stage:Seed, Pre-Seed
  • Geography: Denmark, United States, United Kingdom

Investor stats

  • Total investments: 209
  • Round size: Seed $830k–$5.3M; Pre-Seed $384k–$1.2M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • Deskwolf — Desk Wolf helps SMEs to take advantage of Facebook to generate more sales, more customers, and promote their business in an efficient manner.
  • Advalight — Advalight is a young, dynamic company dedicated to providing high-quality laser equipment for dermatological treatments. The company has patented an innovative technology for use in the removal of vascular lesions, acne treatment, skin rejuvenation and many other skin-enhancing procedures. The ground-breaking product was launched the summer 2014.Advalight is based on five years of scientific work in the Physics Department at the Technical University of Denmark. The founders include two PhDs and it is their research that forms the basis of Advalight. The company's main focus is on research and development and with the right external partners we believe that the market for dermatological lasers will be transformed. Advalight is therefore seeking collaboration with external partners with established distribution and sales channels.
  • CrossEyes — CrossEyes is a Danish optician chain founded in Aarhus in 2010. Our frames are only available in CrossEyes stores and the designs are inspired by current trends and the Scandinavian simplicity.We believe that glasses are not just a tool to see better: They are a fashion accessory and reflects personality and individual style. We get newcollections 10-12 times annually to make sure there’s always news on the shelves – from the everyday classic Original frame to the colorful and trendy Limited.Our vision is to change the eyewear and optical world. We offer a unique customer experience through stunning eyewear, honest pricing, and legendary service. We do this by putting the customer first in every aspect of our business, as we see our customers as ambassadors for our glasses. We strive to give them the best service possible – every time.
Show all investments...

Seed Capital
VC Fund · Copenhagen, Hovedstaden, Denmark · 9 investments in Denmark Biotech startups

Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.

Show more...

Investment focus

  • Industry: Software, Health Care, SaaS
  • Stage:Seed, Series A
  • Geography: Denmark, United States, United Kingdom

Investor stats

  • Total investments: 191
  • Round size: Seed $549k–$5.2M; Series A $3.8M–$17M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: Likely still investing — raised $73M in 2021

Portfolio highlights

  • eloomi — eloomi is an LMS platform for your workplace to train, retain & engage employees. Explore impactful learning & development today.
  • Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
  • Asante Solutions — Asante Solutions was founded more than a decade ago in Denmark. While there, they developed close relationships with a select group of European-based venture capitalists. Backed with venture seed money, they began early stage development of an insulin delivery device that would ultimately become their first product - the Pearl Insulin Pump.
Show all investments...

PSV
VC Fund · Lyngby, Hovedstaden, Denmark · 7 investments in Denmark Biotech startups

PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.

Show more...

Investment focus

  • Industry: Software, Information Technology, SaaS
  • Stage:Seed, Pre-Seed
  • Geography: Denmark, United States, United Kingdom

Investor stats

  • Total investments: 149
  • Round size: Seed $500k–$4.6M; Pre-Seed $353k–$2.5M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — raised $42M in 2020

Portfolio highlights

  • Woba — Woba is a SaaS aiming to support a stress-free work environment and minimise sick leave.
  • Jabbr — Jabbr allows to capture boxing matches with a virtual video production.Its goal is to make video production and advanced performance analytics in combat sports available to anyone with a smartphone.
  • eloomi — eloomi is an LMS platform for your workplace to train, retain & engage employees. Explore impactful learning & development today.
Show all investments...

Sunstone Life Science Ventures
VC Fund · Copenhagen, Hovedstaden, Denmark · 6 investments in Denmark Biotech startups

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B
  • Geography: Denmark, Sweden, Switzerland

Investor stats

  • Total investments: 61
  • Round size: Series A $5.5M–$44M; Series B $9.6M–$52M
  • Lead/follow: 16% lead, 84% follow
  • Last fund: May invest from a new fund soon — raised $94M in 2019

Portfolio highlights

  • Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
  • Resalis Therapeutics — Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche
  • TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Show all investments...

Gilde Healthcare
VC Fund · Utrecht, Utrecht, The Netherlands · 6 investments in Denmark Biotech startups, 7 in the past 12 months

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, The Netherlands, Germany

Investor stats

  • Total investments: 131
  • Round size: Series A $9.5M–$63M; Series B $15M–$135M; Series C $21M–$75M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely still investing — raised $786M in 2023

Portfolio highlights

  • Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
  • GT Medical Technologies — GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors.
  • Endovascular Engineering — Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis.
Show all investments...

Oskare Capital
VC Fund · Paris, Ile-de-France, France · 6 investments in Denmark Biotech startups

Oskare Capital is a venture capital firm.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A, Pre-Seed
  • Geography: Italy, Denmark, United Kingdom

Investor stats

  • Total investments: 9
  • Round size: Seed $1.2M–$3.4M; Series A $4.7M–$5.9M
  • Lead/follow: 56% lead, 44% follow

Portfolio highlights

  • Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
  • Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
  • Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
Show all investments...

Nordic Foodtech VC
VC Fund · Helsinki, Southern Finland, Finland · 6 investments in Denmark Biotech startups

We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food

Show more...

Investment focus

  • Industry: Biotechnology, Food and Beverage, Life Science
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Finland, Denmark, Sweden

Investor stats

  • Total investments: 30
  • Round size: Seed $610k–$5.3M; Pre-Seed $880k–$1.9M; Series A $6.8M–$18M
  • Lead/follow: 57% lead, 43% follow
  • Last fund: Likely still investing — raised $49M in 2021

Portfolio highlights

  • Fiberdom — Fiberdom develops sustainable materials from wood fibers, focusing on plastic-free solutions. The company offers a range of compostable cutlery designed for food service and take-away applications. These products are fully recyclable and comply with European regulations, making them suitable for environmentally conscious consumers. Fiberdomemphasizes innovation in transforming wood fibers into high-performance materials, contributing to sustainability efforts in various industries. The commitment to creating eco-friendly alternatives positions Fiberdom as a key player in the materials innovation sector.
  • Enifer — Enifer Bio is an expert at squeezing every last drop of value from biorefining operations. The solution is built on decades of Finnish expertise to allow the production of valuable protein-rich feed from streams previously considered worthless. The company has developed a new, sustainable production process for high-quality fish feed raw material.The company's method enables the efficient production of a single cell protein from fish by-products as a raw material for fish feed. The protein can replace soy, which is commonly used in fish feed and whose cultivation poses ecological challenges, such as deforestation in South America.
  • MÖ Foods — MÖ Kaurajogu is domestic, completely herbal and above all delicious. All our products are manufactured in Central Ostrobothnia, Lohtaja.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
The Footprint Firm
VC Fund · Copenhagen, Hovedstaden, Denmark · 5 investments in Denmark Biotech startups, 10 in the past 12 months

The Footprint Firm is an advisory and investment company with a sole focus on sustainability.

Show more...

Investment focus

  • Industry: Software, Renewable Energy, Energy Management
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Denmark, Spain, Norway

Investor stats

  • Total investments: 25
  • Round size: Seed $2.2M–$5.4M; Pre-Seed $863k–$4M; Series A $4.7M–$18M
  • Lead/follow: 28% lead, 72% follow

Portfolio highlights

  • Vaja — Vaja is on a mission to accelerate the transition to a net-zero world via disruptive innovations for solar farms.
  • Reel Energy — Reel empowers all companies to procure renewable electricity that makes a real difference for the climate.
  • Kvasir Technologies — Imagine a world without fossil fuelsThis is where we come in! We have invented a solution that makes this possible already in 2050.
Show all investments...

RA Capital Management
VC Fund · Boston, Massachusetts, United States · 5 investments in Denmark Biotech startups

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series C, Post-IPO Equity
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 518
  • Round size: Series B $27M–$152M; Series C $44M–$183M; Post-IPO Equity $35M–$240M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
  • Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.
Show all investments...

2xN
VC Fund · London, England, United Kingdom · 5 investments in Denmark Biotech startups

2xN operates as a venture capital firm.

Show more...

Investment focus

  • Industry: Software, Information Technology, Quantum Computing
  • Stage:Seed, Series A, Series B
  • Geography: Denmark, United States, Finland

Investor stats

  • Total investments: 35
  • Round size: Seed $1.9M–$6.9M; Series A $6.4M–$63M; Series B $15M–$50M
  • Lead/follow: 11% lead, 89% follow

Portfolio highlights

  • Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
  • QSimulate — QSimulate is a simulation platform that solves pressing problems for the chemical and pharmaceutical industries. It aims to deliver best-time-to-solution algorithms to chemical and pharmaceutical industries to accelerate their computational R&D. It is headquartered in Cambridge, Massachusetts.
  • Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
Show all investments...

West Hill Capital
VC Fund · London, England, United Kingdom · 5 investments in Denmark Biotech startups

West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.

Show more...

Investment focus

  • Industry: Software, Health Care, Financial Services
  • Stage:Series A, Seed
  • Geography: United Kingdom, Denmark, Germany

Investor stats

  • Total investments: 60
  • Round size: Seed $2.6M–$6M; Series A $2M–$15M
  • Lead/follow: 83% lead, 17% follow

Portfolio highlights

  • Silicon MicroGravity — Silicon Microgravity Limited is a spin-out from Cambridge University. The underpinning sensor technology was developed through a collaboration with BP plc and provides a breakthrough in the management of oil and gas reservoirs. The technology has been developed in Cambridge University’s Nanoscience Centre primarily funded by BP and Innovate UK.
  • ATLANT 3D — Micro and nanodevices are built and tested within days instead of months or years.
  • Formalize — Formalize delivers a cloud-based compliance operations platform designed for governance, risk, and control workflows, enabling businesses to automate processes around frameworks such as NIS2, DORA, ISO 27001, and GDPR. The platform lets users centralize risk and incident tracking, manage third-party audits and controls, and build customizeddashboards and workflows across compliance, supplier management, and governance.
Show all investments...

HealthCap
VC Fund · Stockholm, Stockholms Lan, Sweden · 4 investments in Denmark Biotech startups

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A
  • Geography: United States, Sweden, France

Investor stats

  • Total investments: 133
  • Round size: Series A $5.7M–$85M; Series B $12M–$92M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: May invest from a new fund soon — raised $209M in 2019

Portfolio highlights

  • Neobiomics — Neobiomics is a Swedish life-science company that develops nutritional products for preterm infants and neonatal care. Its best-known products include ProPrems® and NeoMega36®.
  • CurifyLabs — CurifyLabs enables 3D printed personalized medicines in pharmacies and hospitals. Always close to the patient.
  • Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Show all investments...

ACME Capital
VC Fund · San Francisco, California, United States · 4 investments in Denmark Biotech startups

ACME Capital is a venture capital and private equity firm that invests in breakthrough technologies that fuel platform shifts and disruptive business models that capitalize on new platforms. Its purpose is to support those founders who choose to take their capital. The firm was founded in 2018 and headquartered in San Francisco, California.

Show more...

Investment focus

  • Industry: Software, Health Care, Mobile
  • Stage:Seed, Series A, Series B
  • Geography: United States, Denmark, Canada

Investor stats

  • Total investments: 175
  • Round size: Seed $1.6M–$10M; Series A $4.4M–$30M; Series B $15M–$70M
  • Lead/follow: 22% lead, 78% follow
  • Last fund: Likely still investing — raised $300M in 2022

Portfolio highlights

  • Plot — We power the best creative teams to help streamline creative development and cross-collaborate in one source of truth.
  • NexGenT — Launch Your IT Career in Networking or Cyber Security Online With Our Military Grade Inspired Next Generation Training Programs. Go From Zero To Engineer within 6 months! Zero Up Front Tuition Options Available!
  • Doctor On Demand — 24/7 Online doctors are available. Same week mental health appointments for therapy and psychiatry.
Show all investments...

VF Venture
VC Fund · Hellerup, Hovedstaden, Denmark · 4 investments in Denmark Biotech startups

Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.

Show more...

Investment focus

  • Industry: Software, SaaS, Biotechnology
  • Stage:Seed, Series A
  • Geography: Denmark, United Kingdom, Iceland

Investor stats

  • Total investments: 30
  • Round size: Seed $1.2M–$9.1M; Series A $3.5M–$22M
  • Lead/follow: 30% lead, 70% follow

Portfolio highlights

  • Rokoko — Rokoko | Affordable high-end motion capture and animation tools for body, hand, and face capture + software with native integrations for all major animation software and game engines
  • Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
  • Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
Show all investments...

PINC
VC Fund · Stockholm, Stockholms Lan, Sweden · 4 investments in Denmark Biotech startups

PINC was launched as Paulig Incubator in 2018 to help Paulig stay in the forefront of relevant innovations, as well as to contribute to a tastier, healthier and more sustainable planet. Today, our ambition is the same, but we have developed into a corporate venture arm. We aim for strategic, financial, and societal impact in our investments,fostering a sustainable food system for tomorrow. We are investing across the agrifood value chain in three primary impact themes: Improve planetary health and diet within the current food system: This includes innovations in agriculture and food security, such as advanced crop breeding or green fertilizers, innovative ingredients and next generation healthy foods, as well as solutions for tracking and improving climate and nature. Novel technologies to feed 10 BN people by 2050: Technologies needed to sustainably produce enough food for our growing population. This includes food production without land use change, such as precision fermentation and cell-culture. A circular system for food & materials: Regardless of whether we grow our food in soil or in bioreactors, the system needs to be circular. Some examples are upcycled ingredients, food from unused sources, new coating and packaging solutions, as well as technologies to prevent or make better use of side streams. We are looking for entrepreneurs in an attractive market space with an intrinsic drive to find a solution to the problem they are addressing, a clear and scalable plan for success, a reliable team and partners whom we can trust and work closely with.

Show more...

Investment focus

  • Industry: Biotechnology, Food and Beverage, Agriculture
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Sweden, Denmark, United Kingdom

Investor stats

  • Total investments: 23
  • Round size: Seed $907k–$7M; Pre-Seed $89k–$2.8M; Series A $4.1M–$7.2M
  • Lead/follow: 26% lead, 74% follow

Portfolio highlights

  • Amatera — Amatera is a biotechnology research company that leverages the latest techniques in biotechnology, to create coffee varieties. Amatera urges to make coffee varieties more sustainable and climate resistant to fill that massive demand. Founded by Omar Dekkiche and Lucie Kriegshauser in 2022 and is located in Paris, France.
  • Mycoverse — Mycoverse is a agri-biotech startup specializes in developing fungal-based biological crop protection solutions to replace chemical pesticides, targeting row crops with an initial focus on potato late blight.
  • Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
Show all investments...

DSM Venturing
VC Fund · Heerlen, Limburg, The Netherlands · 4 investments in Denmark Biotech startups

Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Manufacturing
  • Stage:Series A, Series B
  • Geography: United States, Canada, Israel

Investor stats

  • Total investments: 94
  • Round size: Series A $3.5M–$32M; Series B $5.6M–$30M
  • Lead/follow: 51% lead, 49% follow
  • Last fund: May invest from a new fund soon — last raise in 2012

Portfolio highlights

  • Athian — Funding livestock sustainability via a connected carbon marketplace.
  • Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
  • Meala Foodtech — Revolutionary texturized plant proteins that replace eggs and hydrocolloids. Clean-label, allergen-free solutions for baking, savory foods, and dressings.
Show all investments...

Ysios Capital
VC Fund · San Sebastian, Pais Vasco, Spain · 4 investments in Denmark Biotech startups

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: Spain, United States, Switzerland

Investor stats

  • Total investments: 81
  • Round size: Series A $3.8M–$62M; Series B $20M–$135M; Series C $27M–$80M
  • Lead/follow: 30% lead, 70% follow

Portfolio highlights

  • AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
  • Inbiomotion — Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.Inbiomotion's uniquediagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.
  • Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
EIR Ventures
VC Fund · Stockholm, Stockholms Lan, Sweden · 4 investments in Denmark Biotech startups

EIR Ventures is a new Life Science Venture Group in the Nordics.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Seed
  • Geography: Denmark, Sweden, United States

Investor stats

  • Total investments: 13
  • Round size: Series A $20M–$73M
  • Lead/follow: 54% lead, 46% follow
  • Last fund: Likely still investing — raised $143M in 2021

Portfolio highlights

  • ArgusEye — ArgusEye is a biotechnology company that provides sensor solutions for real-time detection of biological systems and processes. ArgusEye's patented sensor technology is the result of extensive academic research and is based on nanoplasmonic sensing with fiber optics. By adding customized receptors, ArgusEye can offer flexible and sensitivesensing systems for a variety of targets.
  • Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
  • Hoba Therapeutics — Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Show all investments...

Atlantic
VC Fund · Berlin, Berlin, Germany · 4 investments in Denmark Biotech startups

Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures.&nbsp;<br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.

Show more...

Investment focus

  • Industry: Software, Health Care, Artificial Intelligence
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 234
  • Round size: Seed $1.3M–$9.4M; Pre-Seed $850k–$3.5M; Series A $5.3M–$30M
  • Lead/follow: 44% lead, 56% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • bonify — Bonify, a Berlin based FinTech-Start-up, enables customers to benefit from their credit scoring and financial data. The company gives customers free and easy access to their credit score and let them upload additional relevant data. Then, it offers tools and personalized recommendations to help optimize the customer’s financial situation.Foundedin 2015 by key executives of McKinsey and Zalando, bonify has received significant funding from internationally leading VCs and successful entrepreneurs.
  • Stenon — Stenon is a laboratory independent real-time soil analyst that offers solutions for agriculture.
  • 42matters — 42matters offers a full suite of mobile and connected TV app intelligence solutions, including APIs, file dumps, and visual, web-based platforms.
Show all investments...

Sofinnova Partners
VC Fund · Paris, Ile-de-France, France · 3 investments in Denmark Biotech startups

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: France, United States, United Kingdom

Investor stats

  • Total investments: 329
  • Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: Likely still investing — raised $200M in 2023

Portfolio highlights

  • Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
  • Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
  • Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
Show all investments...

Unconventional Ventures
VC Fund · Copenhagen, Hovedstaden, Denmark · 3 investments in Denmark Biotech startups, 8 in the past 12 months

Unconventional Ventures invests in startups in the pre-seed and seed stage led by diverse founders identifying as women, people of color, immigrants and/or LGBTQ+, building scalable impact tech companies in the Nordics and beyond.

Show more...

Investment focus

  • Industry: Health Care, Software, Wellness
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Sweden, Denmark, United Kingdom

Investor stats

  • Total investments: 19
  • Round size: Seed $1M–$5.2M; Pre-Seed $1.5M–$2.8M; Series A $4.7M–$18M
  • Lead/follow: 42% lead, 58% follow

Portfolio highlights

  • Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
  • AIRMO — AIRMO is supporting the direct emitters, decision makers and financial institutions to efficiently transition to Net-0 by monitoring their direct emissions from space. With our roots in innovation and a commitment to environmental responsibility, we aim to revolutionize GHG monitoring through advanced satellite technology, proprietary LiDARinstrument and data analytics. We exist to monitor and manage humanity's impact on Earth.
  • Digiclean Solutions — AI-powered process chemical control that gives you lower costs, higher efficiency, and a radically smaller footprint.
Show all investments...

HTGF (High-Tech Gruenderfonds)
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 3 investments in Denmark Biotech startups

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 610
  • Round size: Seed $909k–$7M; Series A $3.5M–$39M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: Likely still investing — raised $522M in 2022

Portfolio highlights

  • CorTec — Reliable products for active implantable device development. We realize your next project with you and offer individual solutions that meet your specific requirements for Medical Devices, especially in neurotechnology.
  • Coinlend — Coinlend - The Lending-Bot for Bitfinex & Liquid Genearate interest from your Bitcoin and Altcoin investments!
  • CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.
Show all investments...

Karolinska
VC Fund · Solna, Stockholms Lan, Sweden · 3 investments in Denmark Biotech startups

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: Sweden, Denmark, United States

Investor stats

  • Total investments: 32
  • Round size: Series A $1.3M–$73M
  • Lead/follow: 34% lead, 66% follow

Portfolio highlights

  • BOOST Pharma — Boost Pharma: Developing a stem cell therapy for Osteogenesis Imperfecta.
  • Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
  • Umecrine Cognition — Umecrine Cognition is a Swedish clinical-stage pharmaceutical company developing a novel class of drugs to treat neurological disorders of the brain.
Show all investments...

Innovation Fund Denmark
VC Fund · Copenhagen, Hovedstaden, Denmark · 3 investments in Denmark Biotech startups

Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.

Show more...

Investment focus

  • Industry: Software, Biotechnology, SaaS
  • Stage:Grant, Pre-Seed, Seed
  • Geography: Denmark, United States

Investor stats

  • Total investments: 96
  • Round size: Seed $66k–$1.3M; Grant $35k–$1.2M; Pre-Seed $64k–$1.6M
  • Lead/follow: 33% lead, 67% follow

Portfolio highlights

  • Prezio — Access comprehensive electricity tariff data across Europe via one API
  • PerPlant — PerPlant gives tractors the ability to see every plant. AI-powered cameras that cut input costs by 50% on average.
  • SureShot — SureShot empowers you and your audience to become video co-creators. With our cutting-edge AI, capture, edit, and share electrifying videos that amplify the essence of every event.
Show all investments...

Bioqube Ventures
VC Fund · Hasselt, Limburg, Belgium · 3 investments in Denmark Biotech startups

Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.

Show more...

Investment focus

  • Industry: Biotechnology, Therapeutics, Life Science
  • Stage:Seed, Series A, Series B
  • Geography: United States, France, Norway

Investor stats

  • Total investments: 18
  • Round size: Seed $5.7M–$24M; Series A $4M–$76M; Series B $23M–$108M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — last raise in 2020

Portfolio highlights

  • Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
  • Spica Therapeutics — Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting technology, Spica identifies and selectively targets disease-relevant macrophage sub
  • Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Show all investments...

Lundbeckfonden Ventures
VC Fund · Copenhagen, Hovedstaden, Denmark · 3 investments in Denmark Biotech startups

Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 70
  • Round size: Series A $10M–$50M; Series B $20M–$95M; Series C $16M–$53M
  • Lead/follow: 33% lead, 67% follow

Portfolio highlights

  • Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
  • SNIPR Biome — We are the CRISPR Microbiome Company; Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.
  • Women in Life Science Denmark — WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.
Show all investments...

Blue Horizon Corporation
VC Fund · Zürich, Zurich, Switzerland · 3 investments in Denmark Biotech startups

Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.

Show more...

Investment focus

  • Industry: Food and Beverage, Food Processing, Biotechnology
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United States, United Kingdom, Germany

Investor stats

  • Total investments: 98
  • Round size: Seed $2M–$12M; Pre-Seed $450k–$6.3M; Series A $2M–$40M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $187M in 2021

Portfolio highlights

  • WOW EARN — Discover WOW EARN, the all-in-one Web3 app with crypto mining, multi-chain wallet, staking NFTs, and marketplace dApps. Join the global Web3 community today.
  • EV Biotech — We design and optimise your precision fermentation strains and processes, tailored to your success.
  • foodforecast — AI supported solution to reduce food waste.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
NOON Ventures
VC Fund · Copenhagen, Hovedstaden, Denmark · 3 investments in Denmark Biotech startups

Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.

Show more...

Investment focus

  • Industry: Biotechnology, AgTech, Farming
  • Stage:Seed, Series A
  • Geography: Denmark

Investor stats

  • Total investments: 6
  • Round size: Seed $4.3M–$8.8M
  • Lead/follow: 83% lead, 17% follow

Portfolio highlights

  • Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
  • Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
  • Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
Show all investments...

Dawn Biopharma
VC Fund · Wilmington, Delaware, United States · 3 investments in Denmark Biotech startups, 6 in the past 12 months

Dawn Biopharma is a global investment firm of KKR.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Seed, Series B
  • Geography: United States, Denmark, France

Investor stats

  • Total investments: 14
  • Round size: Seed $15M–$32M; Series A $17M–$165M; Series B $115M–$135M
  • Lead/follow: 21% lead, 79% follow

Portfolio highlights

  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Vedana Therapeutics — Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
  • Expedition Therapeutics — Redefining Care. Advancing COPD and Other Respiratory Therapies. Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide. ABOUT US At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our
Show all investments...

Thia Ventures
VC Fund · Genève, Geneve, Switzerland · 3 investments in Denmark Biotech startups

WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Manufacturing
  • Stage:Series A, Seed, Pre-Seed
  • Geography: United States, France, Denmark

Investor stats

  • Total investments: 22
  • Round size: Seed $3.4M–$20M; Series A $6.8M–$48M
  • Lead/follow: 14% lead, 86% follow

Portfolio highlights

  • EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
  • uFraction8 — Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable bioprocessing systems.
  • Switch Bioworks — Switch Bioworks engineers symbiotic microbes to produce sustainable nitrogen fertilizer under the control of precise genetic circuits.
Show all investments...

Omega Funds
VC Fund · Boston, Massachusetts, United States · 3 investments in Denmark Biotech startups

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 161
  • Round size: Series A $16M–$187M; Series B $37M–$162M; Series C $14M–$208M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
  • Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
  • Chord Therapeutics — Chord Therapeutics is a clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. We are advancing our lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).
Show all investments...

Ugly Duckling Ventures
VC Fund · Copenhagen, Hovedstaden, Denmark · 3 investments in Denmark Biotech startups, 6 in the past 12 months

At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.

Show more...

Investment focus

  • Industry: Software, Information Technology, Artificial Intelligence
  • Stage:Seed, Pre-Seed, Venture - Series Unknown
  • Geography: Denmark, Sweden, Finland

Investor stats

  • Total investments: 20
  • Round size: Seed $876k–$5.5M; Pre-Seed $917k–$1.7M; Venture - Series Unknown $1.1M–$7.5M
  • Lead/follow: 60% lead, 40% follow

Portfolio highlights

  • Skyfora — Skyfora delivers sub-kilometer insights, nowcasts, and probabilistic forecasts so your teams can plan with confidence, no matter the weather.
  • P-Secure — P-Secure is Europe's only automated platform for EU-compliant background checks. Screening employees, applicants and suppliers in minutes.
  • Financial News Systems — Real-time News for Investment Professionals
Show all investments...

Novo Ventures
VC Fund · Bagsværd, Hovedstaden, Denmark · 2 investments in Denmark Biotech startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 79
  • Round size: Series A $8.5M–$74M; Series B $14M–$75M; Series C $13M–$139M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • Theraxyte — Theraxyte is an innovative nano-drug developer. It focuses on the R&D and application of new nano-drugs, especially innovative drugs.
  • IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
  • Amolyt Pharma — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Show all investments...

+ND Capital
VC Fund · San Mateo, California, United States · 2 investments in Denmark Biotech startups

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, Switzerland, Denmark

Investor stats

  • Total investments: 58
  • Lead/follow: no public data

Portfolio highlights

  • Vandria — At the vanguard of Mitochondrial research
  • Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
  • PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Show all investments...

SR One
VC Fund · Cambridge, Massachusetts, United States · 2 investments in Denmark Biotech startups

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 192
  • Round size: Series A $3.7M–$100M; Series B $15M–$114M; Series C $22M–$175M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Arch Oncology — Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
  • Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation
  • AGTC — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Show all investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 2 investments in Denmark Biotech startups

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 174
  • Round size: Seed $2.4M–$24M; Series A $5.6M–$50M; Series B $15M–$100M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • Cyllene Therapeutics — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
  • iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
  • ApoGen Biotechnologies — Explore fast payout casinos that deliver winnings instantly or under 24 hours. List of the best payout casinos to get same day winnings.
Show all investments...

FundersClub
VC Fund · San Francisco, California, United States · 2 investments in Denmark Biotech startups

FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab.FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more;FundersClub Inc. was founded in 2012 and is based in the United States.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, SaaS
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United States, Canada, India

Investor stats

  • Total investments: 353
  • Round size: Seed $843k–$5.4M; Pre-Seed $450k–$1.7M; Series A $5M–$23M
  • Lead/follow: 6% lead, 94% follow
  • Last fund: May invest from a new fund soon — raised $448k in 2019

Portfolio highlights

  • Purse — The biggest challenge to Bitcoin commerce is the lack of consumer incentive to spend. Purse generates this incentive in the form of 15% discounts on Amazon. Buyers can purchase bitcoins with a credit card as easily as checking out on Amazon, thus solving the last mile problem.
  • Scape — Scape is an AI email client that proactively drafts replies and surfaces what matters. Built for professionals who live in their inbox.
  • Gecko Robotics — To collect and make useful physical data in order to protect civilization's most critical infrastructure
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Megatrend Invest
VC Fund · 2 investments in Denmark Biotech startups

Megatrend Invest is an investment Firm.

Show more...

Investment focus

  • Industry: Biotechnology, Manufacturing
  • Stage:Seed
  • Geography: Denmark

Investor stats

  • Total investments: 2
  • Round size: Seed $3.3M–$10M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Biograil — Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery ofthe biologic efficiently into the gastrointestinal wall.
Show all investments...

Seventure Partners
VC Fund · Paris, Ile-de-France, France · 2 investments in Denmark Biotech startups

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series A, Series B
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 247
  • Round size: Series A $3.3M–$28M; Series B $3.4M–$63M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
  • Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
  • Presto Engineering — We enable companies imagine and implement microelectronics solutions in high-value markets such as Industrial, Automotive, Communication and Medical.
Show all investments...

Balderton Capital
VC Fund · London, England, United Kingdom · 2 investments in Denmark Biotech startups, 26 in the past 12 months

In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.

Show more...

Investment focus

  • Industry: Software, FinTech, Financial Services
  • Stage:Series A, Series B, Series C
  • Geography: United Kingdom, United States, Germany

Investor stats

  • Total investments: 340
  • Lead/follow: no public data

Portfolio highlights

  • Agave Games — Agave Games is a mobile games publishing company and provides unique experiences
  • Grand Games — Grand Games is shaping the future of gaming by creating genre-defining games played by millions worldwide.
  • Lindus Health — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
Show all investments...

Industrifonden
VC Fund · Stockholm, Stockholms Lan, Sweden · 2 investments in Denmark Biotech startups, 7 in the past 12 months

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Series A, Seed
  • Geography: Sweden, United States, Denmark

Investor stats

  • Total investments: 165
  • Lead/follow: no public data

Portfolio highlights

  • Fibbl — Fibbl is the world's first cost-effective end-to-end solution for 3D and AR focused visual marketing. Integrate 3D & AR into e-commerce and marketing in minutes.Fibbl have industrialized the process of producing photorealistic 3D models for consumer products from global brands. Fibbl has the world's largest 3D model database forconsumer products.Learn more - https://www.fibbl.com/
  • Gårdsfisk — Gårdsfisk is a company managing fishing farms. Gårdsfisks develops a new method for fish farming on land. The cultivation takes place in large pools in a closed system, where the nutrient residual water can be reused as fertilizer on the fields.
  • Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Show all investments...

SOSV
VC Fund · Princeton, New Jersey, United States · 2 investments in Denmark Biotech startups, 75 in the past 12 months

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Convertible Note, Pre-Seed
  • Geography: United States, India, United Kingdom

Investor stats

  • Total investments: 1482
  • Lead/follow: no public data

Portfolio highlights

  • MixRift — MIXRIFT - game developers specialized in Mixed Reality
  • unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
  • Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Show all investments...

Aescap Venture
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 2 investments in Denmark Biotech startups

The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies

Show more...

Investment focus

  • Industry: Biotechnology, Pharmaceutical, Chemical
  • Stage:Series A, Series B
  • Geography: United Kingdom, Austria, Belgium

Investor stats

  • Total investments: 18
  • Lead/follow: no public data

Portfolio highlights

  • Orphazyme — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
  • Avantium — Build a sustainable future with Avantium. Leading the change in green chemistry and innovative solutions.
  • F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
Show all investments...

Novo Nordisk
VC Fund · Bagsværd, Hovedstaden, Denmark · 2 investments in Denmark Biotech startups

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Seed, Series B
  • Geography: United States, Denmark, Canada

Investor stats

  • Total investments: 17
  • Round size: Seed $1.6M–$3.5M; Series A $5M–$17M; Series B $38M–$115M
  • Lead/follow: 47% lead, 53% follow

Portfolio highlights

  • Cellular Intelligence — Somite.ai is on a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies.
  • Proton HeartPet — Proton HeartPet is the company in the field of pet intelligent medical care.
  • Cantoni Therapeutics
Show all investments...

Innovations Kapital
VC Fund · Göteborg, Vastra Gotaland, Sweden · 2 investments in Denmark Biotech startups

InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series B, Series C
  • Geography: Sweden, Denmark, United States

Investor stats

  • Total investments: 19
  • Round size: Series B $5.6M–$30M; Series C $5.5M–$15M
  • Lead/follow: 11% lead, 89% follow

Portfolio highlights

  • Silecs — PiBond manufactures materials used in electronic devices, including patterning materials for semiconductors and optical materials. We also develop complete solutions that allow our clients to focus on creating innovative products.
  • SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
  • Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÐMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
Show all investments...

Symrise
VC Fund · Holzminden, Niedersachsen, Germany · 2 investments in Denmark Biotech startups

About 30,000 products - 6,000 customers in roughly 160 countries. First synthesis of vanillin in 1874.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pet
  • Stage:Series A, Corporate Round, Seed
  • Geography: United States, Sweden, Denmark

Investor stats

  • Total investments: 7
  • Round size: Series A $4.2M–$7.2M
  • Lead/follow: 57% lead, 43% follow

Portfolio highlights

  • Cellibre — Cellibre is a cellular agriculture company that turns cells into specialized, sustainable factories for the manufacture of globally significant products at scale.
  • Indevex AB — Indevex is a science-based and privately owned biotech company from Sweden. A natural and reliable partner, providing evidence based natural nutrition concepts based on the patented NGC™ Formula.
  • Bond Pet Foods — We make vegan and protein-rich pet food and treats formulated by board-certified veterinary nutritionists.
Show all investments...

byFounders
VC Fund · Copenhagen, Hovedstaden, Denmark · 2 investments in Denmark Biotech startups, 17 in the past 12 months

byFounders is the community-powered early-stage venture fund investing in globally ambitious teams connected to the Nordic and Baltic countries. With its unique Collective of founders and operators, byFounders offers its portfolio operational expertise and a global network. Believing in the power of tech to shape our future, byFounders takes an impact-aware approach to investing and working with the broader startup ecosystem.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Health Care
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Denmark, United States, Sweden

Investor stats

  • Total investments: 124
  • Round size: Seed $1.5M–$9.4M; Pre-Seed $800k–$4.2M; Series A $6.1M–$65M
  • Lead/follow: 51% lead, 49% follow
  • Last fund: May invest from a new fund soon — raised $117M in 2021

Portfolio highlights

  • Visoid — Render your 3D models with ease! Quick and easy rendering software for architects, powered by AI. Try Visoid for free!
  • Verda (formerly DataCrunch) — DataCrunch is a cloud service provider which facilitates utilization and integration of state of the art AI/ML models
  • Spiral Hydrogen — All-in-one, bubble-free centrifugal electrolyzer with an embedded axial flux generator that sets a new standard in efficiency and simplicity.
Show all investments...

Biotech VC funding in Denmark at a glance

Stats across 391 deals from 351 investors.

351
investors
in Denmark Biotech startups
391
deals
in Denmark Biotech startups
$4.2M
median round
in Denmark Biotech startups
49%
lead investors
lead at least one round
19%
Seed
most common funding stage

Access all 351 VC funds in Denmark Biotech startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotech VC Funds in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 351 VC funds investing in Denmark Biotech startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists

Broader lists